Effects of the Omicron variant of coronavirus disease 2019 on anaemia treatment for patients undergoing peritoneal dialysis

Qinghua Yang,Xiaowan Fang,Xiaoying Ren,Yujing Pan,Mei Wang,Jiaxiang Ding
DOI: https://doi.org/10.1111/nep.14274
2024-02-22
Nephrology
Abstract:Summary at a glance This retrospective study aimed to assess changes in haemoglobin levels and explore the effectiveness of roxadustat and recombinant human erythropoietin for the treatment of anaemia in patients infected with the Omicron variant of COVID‐19 at Peking University International Hospital between November 2022 and February 2023. Aim Patients undergoing dialysis are at high risk for coronavirus disease 2019 (COVID‐19). Haemoglobin (Hb) levels may be changed in patients infected with the Omicron variant of COVID‐19 who are undergoing peritoneal dialysis (PD). Therefore, we aimed to explore the effect of anti‐anaemia treatment on such patients. Methods This study enrolled patients undergoing PD who were infected with the Omicron variant of COVID‐19 at our centre between November 2022 and February 2023. We retrospectively analysed changes in Hb levels and explored the effectiveness of roxadustat and recombinant human erythropoietin (rhEPO) for patients infected with the Omicron variant of COVID‐19. Results Among 125 enrolled patients, 83 (66.4%) were infected with the Omicron variant and 75 (90.4%) patients mainly experienced mild or moderate disease. During infection, C‐reactive protein (CRP) levels were higher than those before infection (p
urology & nephrology
What problem does this paper attempt to address?